Skip to main content

Byooviz Side Effects

Generic name: ranibizumab ophthalmic

Medically reviewed by Drugs.com. Last updated on Jun 5, 2023.

Note: This document contains side effect information about ranibizumab ophthalmic. Some dosage forms listed on this page may not apply to the brand name Byooviz.

Applies to ranibizumab ophthalmic: intraocular implant, intraocular solution. Other dosage forms:

Warning

Intraocular route (Implant)

Warning: EndophthalmitisThe ranibizumab implant has been associated with a 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. Many of these events were associated with conjunctival retractions or erosions. Appropriate conjunctiva management and early detection with surgical repair of conjunctival retractions or erosions may reduce the risk of endophthalmitis. In clinical trials, 2% of patients receiving a ranibizumab implant experienced at least one episode of endophthalmitis.

Serious side effects of Byooviz

Along with its needed effects, ranibizumab ophthalmic (the active ingredient contained in Byooviz) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking ranibizumab ophthalmic:

More common

Less common

Other side effects of Byooviz

Some side effects of ranibizumab ophthalmic may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to ranibizumab ophthalmic: intravitreal solution.

Ocular

-Very common (10% or more): Conjunctival hemorrhage (up to 74%), eye pain (up to 35%), vitreous floaters (up to 27%), increased intraocular pressure (up to 24%), vitreous detachment (up to 21%), intraocular inflammation (up to 18%), vision disturbance/blurred vision (up to 18%), cataract (up to 17%), foreign body sensation in eyes (up to 16%), eye irritation (up to 15%), increased lacrimation (up to 14%), blepharitis (up to 12%), dry eye (up to 12%), eye pruritus (up to 12%), ocular hyperemia (up to 11%), maculopathy (up to 11%), retinal disorder (10%), vitreitis, retinal hemorrhage

-Common (1% to 10%): Retinal degeneration, retinal detachment, retinal tear, retinal pigment epithelium detachment, retinal pigment epithelium tear, reduced visual acuity, vitreous hemorrhage, vitreous disorder, uveitis, iritis, iridocyclitis, subcapsular cataract, punctuate keratitis, corneal abrasion, anterior chamber flare, eye hemorrhage, conjunctivitis, allergic conjunctivitis, eye discharge, photopsia, photophobia, ocular discomfort, eyelid edema, eyelid pain, conjunctival hyperemia, posterior capsule opacification, endophthalmitis, injection site hemorrhage

-Uncommon (0.1% to 1%): Blindness, endophthalmitis, hypopyon, hyphema, keratopathy, iris adhesion, corneal deposits, corneal edema, corneal striae, injection site pain, injection site irritation, abnormal sensation in eye, eyelid irritation[Ref]

Respiratory

Very common (10% or more): Nasopharyngitis (up to 16%), bronchitis (up to 11%)

Common (1% to 10%): Cough, upper respiratory tract infection, sinusitis, chronic obstructive pulmonary disease[Ref]

Nervous system

Very common (10% or more): Headache (up to 12%)

Common (1% to 10%): Peripheral neuropathy, stroke[Ref]

Hematologic

Very common (10% or more): Anemia (up to 11%)[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia (up to 11%)[Ref]

Cardiovascular

Very common (10% or more): Arterial thromboembolic events (up to 10.8%)

Common (1% to 10%): Peripheral edema, atrial fibrillation[Ref]

Gastrointestinal

Very common (10% or more): Nausea (up to 10%)

Common (1% to 10%): Constipation, gastroesophageal reflux disease[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection[Ref]

Hypersensitivity

Common (1% to 10%): Hypersensitivity reactions[Ref]

Immunologic

Common (1% to 10%): Immunoreactivity, seasonal allergy, allergic reactions (rash, urticaria, pruritus, erythema)[Ref]

Metabolic

Common (1% to 10%): Hypercholesterolemia[Ref]

Other

Common (1% to 10%): Influenza, would healing complications, fatal events

Frequency not reported: Non-ocular hemorrhage[Ref]

Psychiatric

Common (1% to 10%): Anxiety[Ref]

Renal

Common (1% to 10%): Renal failure, chronic renal failure[Ref]

Frequently asked questions

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Product Information. Lucentis (ranibizumab ophthalmic). Genentech. 2006.

3. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.